FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Retatrutide vs Mounjaro: Blood Sugar, Weight Loss and Price (2026)

Bright clinical chemistry lab with three white automated analyzers and racks of small capped sample tubes along a wall under tall windows

Mounjaro and retatrutide come from the same company and the same idea. Mounjaro is tirzepatide, Eli Lilly’s weekly shot for type 2 diabetes, approved in the US in May 2022. Retatrutide is the molecule Lilly built after it, with one more hormone receptor in its sights, and it isn’t approved anywhere yet.

That gap in status hides how closely the two can now be lined up. In March 2026 retatrutide reported its first diabetes trial, and it was built almost exactly like the trial behind Mounjaro’s approval: 40 weeks, people managing on diet and exercise alone, the same average starting A1C of 7.9%. Blood sugar came out close to even. Weight didn’t: 16.8% off on retatrutide’s top dose, 11.0% on Mounjaro’s.

Simms Research sells retatrutide for laboratory research as Retatrutide (GLP-3), a freeze-dried powder whose batch certificate records how much is actually in the vial.

Are retatrutide and Mounjaro the same?

No. They are two separate Lilly molecules, and only one of them can be filled at a pharmacy.

Mounjaro is the diabetes brand of tirzepatide, which works on two gut-hormone receptors, GIP and GLP-1. Its US label covers type 2 diabetes in adults and, since December 2025, in children from age 10. In August 2026 it gained a second use: cutting the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who are at high risk of them. In the US the same molecule is sold for weight loss under another name, Zepbound. In the UK and the European Union, Mounjaro’s own label covers weight management too, which is why so many people abroad know it as a weight-loss shot.

Retatrutide takes tirzepatide’s two receptors and adds a third, the glucagon receptor, which raises the energy the body burns and pulls fat out of the liver. That third target is behind most of the gap in weight results below; the full picture of what retatrutide is sits on its own page. Lilly plans to file it with the FDA in the first quarter of 2027. The molecules are set side by side in retatrutide vs tirzepatide, and the weight-loss brand gets its own match-up in retatrutide vs Zepbound.

Glass flasks of pale yellow solution with white foam stoppers clamped on a lab shaker platform by a sunny window

Retatrutide vs Mounjaro for diabetes

On blood sugar they finish level. Each took A1C down by about two points from 7.9% in a 40-week trial, and neither caused a severe low.

The two trials are close to twins. TRANSCEND-T2D-1 gave retatrutide to 537 adults with type 2 diabetes (Bajaj, The Lancet, 2026); SURPASS-1 gave Mounjaro to 478 (Rosenstock, The Lancet, 2021). Both enrolled people treated with diet and exercise alone, ran 40 weeks, tested three doses against placebo and climbed to each dose in four-week steps. Each figure below is the trial’s result for people who kept taking their assigned dose:

GroupA1C changeWeight changeNauseaStopped for side effects
Retatrutide 4mg−1.7 points−24.5 lb16.4%2.2%
Retatrutide 9mg−2.0 points−33.3 lb19.5%4.5%
Retatrutide 12mg−1.9 points−36.6 lb26.5%5.1%
Placebo, retatrutide trial−0.8 points−6.2 lb3.7%0.0%
Mounjaro 5mg−1.9 points−15.4 lb11.6%3.3%
Mounjaro 10mg−1.9 points−17.2 lb13.2%5.0%
Mounjaro 15mg−2.1 points−20.9 lb18.2%6.6%
Placebo, Mounjaro trial0.0 points−1.5 lb6.1%2.6%

The A1C column barely separates them. Every dose of both drugs landed within a few tenths of two points, which brought the average reading from 7.9% to around 6%. In SURPASS-1, 87% to 92% of people on Mounjaro finished under 7%, the usual target. Retatrutide’s placebo group dropped 0.8 points on its own while Mounjaro’s stayed flat, so measured against placebo, Mounjaro’s blood sugar effect reads larger.

The weight column is where they split. Retatrutide 4mg, a single step above its 2mg start, edged past Mounjaro 15mg, the top of the label: 11.5% of body weight against 11.0%. Retatrutide 12mg took off 16.8%. People in the retatrutide trial started heavier, about 214 lb against about 189 lb, so the pounds flatter it a little, but the percentages carry the same gap. And retatrutide’s weight was still coming down at week 40, with no sign of a plateau.

Retatrutide vs Mounjaro vs Ozempic

Both have beaten semaglutide, the drug in Ozempic, head to head. Retatrutide beat it by a wider margin on weight, against a stronger dose.

Mounjaro met semaglutide 1mg in SURPASS-2: 1,879 adults already taking metformin, 40 weeks. A1C fell 2.30 points on Mounjaro 15mg against 1.86 on semaglutide, and weight fell 11.2 kg (24.7 lb) against 5.7 kg (12.6 lb) (Frías, New England Journal of Medicine, 2021).

Retatrutide met Ozempic at 2mg, its highest approved dose, in TRANSCEND-T2D-2: 1,298 adults on metformin, 80 weeks, results released on October 28, 2026. A1C fell 2.2 points on both 9mg and 12mg against 1.8 on Ozempic, from a starting average of 8.3%. Weight fell 20.9% on 12mg, or 47.4 lb, against 9.4% on Ozempic.

The common opponent tells the same story as the twin trials. Each drug beat semaglutide on A1C by about half a point, so on blood sugar neither pulls ahead of the other. On weight, Mounjaro about doubled semaglutide’s loss, and retatrutide more than doubled Ozempic’s while facing twice the semaglutide dose. TRANSCEND-T2D-2 was retatrutide’s first Phase 3 trial against another drug of its class; the one against tirzepatide itself, TRIUMPH-5, hasn’t reported.

Empty bright measurement room with a standing scale with hand grips and a wall-mounted height rod beside a tall window

Retatrutide vs Mounjaro weight loss

Retatrutide takes off more in every trial that can be compared: 16.8% against 11.0% over 40 weeks in type 2 diabetes, and about 21% against about 16% over a year and a half in people with diabetes and obesity.

Diabetes holds weight loss back on all of these drugs, so the figures here sit below the obesity trials on both sides. The longer diabetes trials kept the order of the 40-week ones. In TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes lost 20.8% on retatrutide 12mg over 80 weeks, about 50 lb, against 4.0% on placebo. Tirzepatide’s matching trial, SURMOUNT-2, reached 15.7% on 15mg over 72 weeks. TRANSCEND-T2D-2 landed in the same place as TRIUMPH-2, at 20.9%, so across retatrutide’s diabetes program 12mg ran from about 17% of body weight at 40 weeks to about 21% at 80.

On both drugs most of the weight that comes off is fat, and lean tissue makes up about the share seen with other weight-loss drugs; muscle loss on retatrutide goes through the body scans. For people without diabetes, both compounds go further, and those obesity trials are compared in retatrutide vs Zepbound.

Retatrutide vs Mounjaro side effects

Both bring the same stomach side effects, more often on retatrutide’s higher doses, and retatrutide adds a skin-sensation effect that Mounjaro rarely causes.

In the twin diabetes trials, vomiting reached 15.0% to 17.6% across retatrutide’s doses against 2.2% on its placebo, and 2.5% to 5.8% on Mounjaro against 1.7%. Diarrhea ran 18.7% to 26.3% on retatrutide and 11.6% to 14.0% on Mounjaro. Most of it was mild to moderate and clustered in the weeks after each dose step, then eased.

In the matched trials, more stomach trouble didn’t mean more people quitting: over 40 weeks, 5.1% stopped retatrutide 12mg because of side effects against 6.6% on Mounjaro 15mg. Against Ozempic over 80 weeks, retatrutide 12mg was the one more people stopped: 7.9% against 2.7%.

The one that sets retatrutide apart from Mounjaro is dysesthesia, skin that tingles, burns or feels oddly sensitive to touch. It showed up in 2.3% to 4.5% of people in TRANSCEND-T2D-1 and none on placebo, was mostly mild and mostly cleared while treatment went on. Rates by dose across every trial are in retatrutide side effects, and Mounjaro’s molecule has its own list in tirzepatide side effects.

Ball-and-stick model of a peptide chain lying across a white lab bench beside a small glass vial of white freeze-dried powder

Retatrutide vs Mounjaro dosage and equivalent dose

Mounjaro runs from 2.5mg to 15mg a week, retatrutide’s trials from 2mg to 12mg. The milligrams don’t convert one to one, because each molecule pulls on its receptors with a different strength.

Mounjaro starts at 2.5mg once a week and goes up 2.5mg at a time, after at least four weeks on each dose, when blood sugar needs more help. The ceiling is 15mg for adults and 10mg for children. Retatrutide’s Phase 3 trials started everyone at 2mg and stepped up every four weeks through 4mg, 6mg and 9mg to 12mg, stopping at the dose each person was assigned. The week-by-week schedule is in the retatrutide dosage chart.

Retatrutide to Mounjaro equivalent dose

Matched by result, retatrutide 4mg is the counterpart of Mounjaro 15mg in type 2 diabetes. In the twin trials the two lowered A1C by about the same amount, and 4mg took off 11.5% of body weight to Mounjaro 15mg’s 11.0%. Retatrutide 9mg and 12mg sit beyond anything on Mounjaro’s label. Moving from one to the other is its own topic, covered in switching from tirzepatide to retatrutide.

Pens and vials vs research powder

Mounjaro comes ready to inject, as a clear liquid. It’s sold in single-dose pens, four to a carton, in single-dose vials, and in multi-dose vials and KwikPens that each hold four weekly doses. Those four-dose packs run from 10mg, for four 2.5mg doses, up to 60mg, for four 15mg doses.

Research retatrutide comes as a freeze-dried powder that gets mixed with bacteriostatic water, such as Research Water, before use. Its vials share four of Mounjaro’s pack sizes, 10mg, 20mg, 30mg and 60mg, and each holds five weeks at the trial step it matches, from 2mg a week in the 10mg vial to 12mg a week in the 60mg. How to Reconstitute Retatrutide gives the water for each size, and the retatrutide calculator turns a dose into syringe units.

Retatrutide vs Mounjaro price

Mounjaro lists at $1,112.16 a month and sells for $499 a month without insurance. Retatrutide has no pharmacy price; a month of the research powder runs from about $73 to about $224, depending on the dose.

Mounjaro’s list price, set on January 1, 2026, covers a month of four pens and is the same at every dose, though insurance decides what most people actually pay. With a prescription, Lilly sells the single-dose pens directly from $499 a month at any strength from 2.5mg to 15mg, and people whose commercial insurance covers Mounjaro can pay as little as $25 for up to three months with Lilly’s savings card. Medicare and Medicaid members can’t use the card.

Retatrutide won’t have a list price before approval; until then it’s sold for laboratory research. Simms Research prices Retatrutide (GLP-3) at $84 for 10mg, $129 for 20mg, $159 for 30mg and $259 for 60mg, from $8.40 down to $4.32 per milligram. At 12mg a week the 60mg vial lasts five weeks, $51.80 a week; retatrutide cost per month works out every dose. Its current batch, tested on July 16, 2026 by an independent ISO-certified lab, came back at 99.611% purity with 10.68mg measured in vials labelled 10mg; the certificate is under retatrutide lab results. Mounjaro’s own molecule is stocked for research too, as Tirzepatide (GLP-2), from $65 for 10mg.

Is retatrutide better than Mounjaro?

For weight, yes. In every diabetes trial that can be lined up, retatrutide took off more, and its lowest maintenance dose matched Mounjaro’s highest. For blood sugar, they tie: both cut A1C by about two points and both beat semaglutide by about half a point.

Mounjaro’s lead is its record. It has been approved since 2022, it is cleared for children from age 10, and it has a finished heart-outcomes trial: SURPASS-CVOT followed 13,299 people with diabetes and heart disease for a median of about four years, and that result added the heart-risk use to its label in August 2026. Retatrutide’s own heart and kidney outcomes trial runs to 2029. Mounjaro also comes with a price, a pharmacy and insurance cover today; retatrutide comes with six positive Phase 3 trials and a filing date.

Frequently asked questions

Is retatrutide stronger than Mounjaro?

On weight, yes: 16.8% at 12mg against 11.0% at Mounjaro 15mg over 40 weeks in type 2 diabetes. On A1C the two are level, about two points each.

What dose of retatrutide equals Mounjaro 15mg?

In type 2 diabetes, 4mg: it matched Mounjaro 15mg on A1C and edged it on weight, 11.5% against 11.0%.

Can you switch from Mounjaro to retatrutide?

No trial has tested a switch, and every retatrutide Phase 3 trial started people at 2mg. The move is covered step by step in switching from tirzepatide to retatrutide.

Is retatrutide FDA approved?

Not yet. Lilly plans to file in the first quarter of 2027, and When Will Retatrutide Be FDA Approved? follows the timeline.

Is Simms Research legit?

Its retatrutide lab results show the full certificate for the current batch, including the 10.68mg measured in 10mg vials. Orders ship the same or next business day, the same day before 5PM Eastern, and a lost, stolen or damaged delivery is replaced at no charge. Support answers at 855-592-8507 and support@simmsresearch.com.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results